1) Andersen, P. M., & Al-Chalabi, A. (2011). Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 7(11), 603-615.
2) Anjana, R., Vaishnavi, M. K., Sherlin, D., Kumar, S. P., Naveen, K., Kanth, P. S., et al. (2012). Aromatic-aromatic interactions in structures of proteins and protein-DNA complexes: a study based on orientation and distance. Bioinformation. 8(24), 1220-1224.
3) Anzai, I., Tokuda, E., Mukaiyama, A., Akiyama, S., Endo, F., Yamanaka, K., et al. (2017). A misfolded dimer of Cu/Zn-superoxide dismutase leading to pathological oligomerization in amyotrophic lateral sclerosis. Protein Sci. 26(3), 484-496.
4) Averill, D. R., Jr. (1973). Degenerative myelopathy in the aging German Shepherd dog: clinical and pathologic findings. J Am Vet Med Assoc. 162(12), 1045-1051.
5) Awano, T., Johnson, G. S., Wade, C. M., Katz, M. L., Johnson, G. C., Taylor, J. F., et al. (2009). Genome-wide association analysis reveals a SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 106(8), 2794-2799.
6) Azriel, R., & Gazit, E. (2001). Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide. An experimental support for the key role of the phenylalanine residue in amyloid formation. J Biol Chem. 276(36), 34156-34161.
7) Benatar, M. (2007). Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis. 26(1), 1-13.
8) Bruijn, L. I., Miller, T. M., & Cleveland, D. W. (2004). Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 27, 723-749.
9) Calamai, M., Taddei, N., Stefani, M., Ramponi, G., & Chiti, F. (2003). Relative influence of hydrophobicity and net charge in the aggregation of two homologous proteins. Biochemistry. 42(51), 15078-15083.
10) Chang, H. S., Kamishina, H., Mizukami, K., Momoi, Y., Katayama, M., Rahman, M. M., et al. (2013). Genotyping assays for the canine degenerative myelopathy-associated c.118G>A (p.E40K) mutation of the SOD1 gene using conventional and real-time PCR methods: a high prevalence in the Pembroke Welsh Corgi breed in Japan. J Vet Med Sci. 75(6), 795-798.
11) Chang, R. C., Parakh, S., Coates, J. R., Long, S., & Atkin, J. D. (2019). Protein disulphide isomerase is associated with mutant SOD1 in canine degenerative myelopathy. Neuroreport. 30(1), 8-13.
12) Chaudhuri, T. K., & Paul, S. (2006). Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J. 273(7), 1331-1349.
13) Chen, Z., & Zhong, C. (2014). Oxidative stress in Alzheimer's disease. Neurosci Bull. 30(2), 271-281.
14) Chiti, F., Calamai, M., Taddei, N., Stefani, M., Ramponi, G., & Dobson, C. M. (2002). Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. Proc Natl Acad Sci U S A. 99 Suppl 4, 16419-16426.
15) Cleveland, D. W., & Rothstein, J. D. (2001). From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2(11), 806-819.
16) Coates, J. R., March, P. A., Oglesbee, M., Ruaux, C. G., Olby, N. J., Berghaus, R. D., et al. (2007). Clinical characterization of a familial degenerative myelopathy in Pembroke Welsh Corgi dogs. J Vet Intern Med. 21(6), 1323-1331.
17) Coates, J. R., & Wininger, F. A. (2010). Canine degenerative myelopathy. Vet Clin North Am Small Anim Pract. 40(5), 929-950.
18) Cozzolino, M., Ferri, A., Valle, C., & Carri, M. T. (2013). Mitochondria and ALS:implications from novel genes and pathways. Mol Cell Neurosci. 55, 44-49.
19) Crisp, M. J., Beckett, J., Coates, J. R., & Miller, T. M. (2013). Canine degenerative myelopathy: biochemical characterization of superoxide dismutase 1 in the first naturally occurring non-human amyotrophic lateral sclerosis model. Exp Neurol. 248, 1-9.
20) Crown, A. M., Roberts, B. L., Crosby, K., Brown, H., Ayers, J. I., Hart, P. J., et al. (2019). Experimental Mutations in Superoxide Dismutase 1 Provide Insight into Potential Mechanisms Involved in Aberrant Aggregation in Familial Amyotrophic Lateral Sclerosis. G3 (Bethesda). 9(3), 719-728.
21) Dion, P. A., Daoud, H., & Rouleau, G. A. (2009). Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nat Rev Genet. 10(11), 769-782.
22) Doyle, K. M., Kennedy, D., Gorman, A. M., Gupta, S., Healy, S. J., & Samali, A. (2011). Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. J Cell Mol Med. 15(10), 2025-2039.
23) Furukawa, Y., Anzai, I., Akiyama, S., Imai, M., Cruz, F. J., Saio, T., et al. (2016). Conformational Disorder of the Most Immature Cu, Zn-Superoxide Dismutase Leading to Amyotrophic Lateral Sclerosis. J Biol Chem. 291(8), 4144-4155.
24) Furukawa, Y., & O'Halloran, T. V. (2005). Amyotrophic lateral sclerosis mutations have the greatest destabilizing effect on the apo- and reduced form of SOD1, leading to unfolding and oxidative aggregation. J Biol Chem. 280(17), 17266-17274.
25) Furuta, K., Kawai, Y., Mizuno, Y., Hattori, Y., Koyama, H., & Hirata, Y. (2017). Synthesis of 3-[4-(dimethylamino)phenyl]alkyl-2-oxindole derivatives and their effects on neuronal cell death. Bioorg Med Chem Lett. 27(18), 4457-4461.
26) Furuta, K., Mizuno, Y., Maeda, M., Koyama, H., & Hirata, Y. (2017). Synthesis of 3- Arylmethyl-2-oxindole Derivatives and Their Effects on Neuronal Cell Death. Chem Pharm Bull (Tokyo). 65(11), 1093-1097.
27) Gazit, E. (2002). A possible role for pi-stacking in the self-assembly of amyloid fibrils. FASEB J. 16(1), 77-83.
28) Hayward, C., Brock, D. J., Minns, R. A., & Swingler, R. J. (1998). Homozygosity for Asn86Ser mutation in the CuZn-superoxide dismutase gene produces a severe clinical phenotype in a juvenile onset case of familial amyotrophic lateral sclerosis. J Med Genet. 35(2), 174.
29) Hayward, L. J., Rodriguez, J. A., Kim, J. W., Tiwari, A., Goto, J. J., Cabelli, D. E., et al. (2002). Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis. J Biol Chem. 277(18), 15923-15931.
30) Hetz, C. (2012). The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 13(2), 89-102.
31) Higurashi, T., Nosaka, K., Mizobata, T., Nagai, J., & Kawata, Y. (1999). Unfolding and refolding of Escherichia coli chaperonin GroES is expressed by a three-state model. J Mol Biol. 291(3), 703-713.
32) Hirata, Y., Ito, Y., Takashima, M., Yagyu, K., Oh-Hashi, K., Suzuki, H., et al. (2020). Novel Oxindole-Curcumin Hybrid Compound for Antioxidative Stress and Neuroprotection. ACS Chem Neurosci. 11(1), 76-85.
33) Hirata, Y., Yamada, C., Ito, Y., Yamamoto, S., Nagase, H., Oh-Hashi, K., et al. (2018). Novel oxindole derivatives prevent oxidative stress-induced cell death in mouse hippocampal HT22cells. Neuropharmacology. 135, 242-252.
34) Hock, C., Konietzko, U., Papassotiropoulos, A., Wollmer, A., Streffer, J., von Rotz, R. C., et al. (2002). Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med. 8(11), 1270-1275.
35) Kabashi, E., Agar, J. N., Taylor, D. M., Minotti, S., & Durham, H. D. (2004). Focal dysfunction of the proteasome: a pathogenic factor in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 89(6), 1325-1335.
36) Kato, S., Nakashima, K., Horiuchi, S., Nagai, R., Cleveland, D. W., Liu, J., et al. (2001). Formation of advanced glycation end-product-modified superoxide dismutase-1 (SOD1) is one of the mechanisms responsible for inclusions common to familial amyotrophic lateral sclerosis patients with SOD1 gene mutation, and transgenic mice expressing human SOD1 gene mutation. Neuropathology. 21(1), 67-81.
37) Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., et al. (2011). Amyotrophic lateral sclerosis. Lancet. 377(9769), 942-955.
38) Kobatake, Y., Sakai, H., Tsukui, T., Yamato, O., Kohyama, M., Sasaki, J., et al. (2017). Localization of a mutant SOD1 protein in E40K-heterozygous dogs: Implications for non- cell-autonomous pathogenesis of degenerative myelopathy. J Neurol Sci. 372, 369-378.
39) Lee, S., & Eisenberg, D. (2003). Seeded conversion of recombinant prion protein to a disulfide-bonded oligomer by a reduction-oxidation process. Nat Struct Biol. 10(9), 725-730.
40) Lindquist, S. L., & Kelly, J. W. (2011). Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb Perspect Biol. 3(12).
41) Lozupone, M., Solfrizzi, V., D'Urso, F., Di Gioia, I., Sardone, R., Dibello, V., et al. (2020). Anti-amyloid-beta protein agents for the treatment of Alzheimer's disease: an update on emerging drugs. Expert Opin Emerg Drugs. 25(3), 319-335.
42) Mandrioli, L., Gandini, G., Gentilini, F., Chiocchetti, R., Turba, M. E., Avallone, G., et al. (2021). Degenerative Myelopathy in Hovawart Dogs: Molecular Characterization, Pathological Features and Accumulation of Mutant Superoxide Dismutase 1 Protein. J Comp Pathol. 182, 37-42.
43) March, P. A., Coates, J. R., Abyad, R. J., Williams, D. A., O'Brien, D. P., Olby, N. J., et al. (2009). Degenerative myelopathy in 18 Pembroke Welsh Corgi dogs. Vet Pathol. 46(2), 241-250.
44) Miller, A. D., Barber, R., Porter, B. F., Peters, R. M., Kent, M., Platt, S. R., et al. (2009). Degenerative myelopathy in two Boxer dogs. Vet Pathol. 46(4), 684-687.
45) Mohamed, F. E., Al-Gazali, L., Al-Jasmi, F., & Ali, B. R. (2017). Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises. Front Pharmacol. 8, 448.
46) Munch, C., & Bertolotti, A. (2010). Exposure of hydrophobic surfaces initiates aggregation of diverse ALS-causing superoxide dismutase-1 mutants. J Mol Biol. 399(3), 512-525.
47) Nakamae, S., Kobatake, Y., Suzuki, R., Tsukui, T., Kato, S., Yamato, O., et al. (2015). Accumulation and aggregate formation of mutant superoxide dismutase 1 in canine degenerative myelopathy. Neuroscience. 303, 229-240.
48) Nikseresht, S., Hilton, J. B. W., Kysenius, K., Liddell, J. R., & Crouch, P. J. (2020). Copper-ATSM as a Treatment for ALS: Support from Mutant SOD1 Models and Beyond. Life (Basel). 10(11).
49) Niwa, J., Yamada, S., Ishigaki, S., Sone, J., Takahashi, M., Katsuno, M., et al. (2007). Disulfide bond mediates aggregation, toxicity, and ubiquitylation of familial amyotrophic lateral sclerosis-linked mutant SOD1. J Biol Chem. 282(38), 28087-28095.
50) Ogawa, M., Uchida, K., Park, E. S., Kamishina, H., Sasaki, J., Chang, H. S., et al. (2011). Immunohistochemical observation of canine degenerative myelopathy in two Pembroke Welsh Corgi dogs. J Vet Med Sci. 73(10), 1275-1279.
51) Oyake, K., Kobatake, Y., Shibata, S., Sakai, H., Saito, M., Yamato, O., et al. (2016). Changes in respiratory function in Pembroke Welsh Corgi dogs with degenerative myelopathy. J Vet Med Sci. 78(8), 1323-1327.
52) Pfahler, S., Bachmann, N., Fechler, C., Lempp, C., Baumgartner, W., & Distl, O. (2014). Degenerative myelopathy in a SOD1 compound heterozygous Bernese mountain dog. Anim Genet. 45(2), 309-310.
53) Reaume, A. G., Elliott, J. L., Hoffman, E. K., Kowall, N. W., Ferrante, R. J., Siwek, D. F., et al. (1996). Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet. 13(1), 43-47.
54) Richter, M., Vidovic, N., Honrath, B., Mahavadi, P., Dodel, R., Dolga, A. M., et al. (2016). Activation of SK2 channels preserves ER Ca(2)(+) homeostasis and protects against ER stress-induced cell death. Cell Death Differ. 23(5), 814-827.
55) Robberecht, W., Sapp, P., Viaene, M. K., Rosen, D., McKenna-Yasek, D., Haines, J., et al. (1994). Cu/Zn superoxide dismutase activity in familial and sporadic amyotrophic lateral sclerosis. J Neurochem. 62(1), 384-387.
56) Roberts, B. R., Lim, N. K., McAllum, E. J., Donnelly, P. S., Hare, D. J., Doble, P. A., et al. (2014). Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci. 34(23), 8021-8031.
57) Rodriguez, J. A., Shaw, B. F., Durazo, A., Sohn, S. H., Doucette, P. A., Nersissian, A. M., et al. (2005). Destabilization of apoprotein is insufficient to explain Cu,Zn-superoxide dismutase-linked ALS pathogenesis. Proc Natl Acad Sci U S A. 102(30), 10516-10521.
58) Rodriguez, J. A., Valentine, J. S., Eggers, D. K., Roe, J. A., Tiwari, A., Brown, R. H., Jr., et al. (2002). Familial amyotrophic lateral sclerosis-associated mutations decrease the thermal stability of distinctly metallated species of human copper/zinc superoxide dismutase. J Biol Chem. 277(18), 15932-15937.
59) Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 362(6415), 59-62.
60) Sandelin, E., Nordlund, A., Andersen, P. M., Marklund, S. S., & Oliveberg, M. (2007). Amyotrophic lateral sclerosis-associated copper/zinc superoxide dismutase mutations preferentially reduce the repulsive charge of the proteins. J Biol Chem. 282(29), 21230- 21236.
61) Shaw, B. F., & Valentine, J. S. (2007). How do ALS-associated mutations in superoxide dismutase 1 promote aggregation of the protein? Trends Biochem Sci. 32(2), 78-85.
62) Shibata, N., Hirano, A., Kobayashi, M., Siddique, T., Deng, H. X., Hung, W. Y., et al. (1996). Intense superoxide dismutase-1 immunoreactivity in intracytoplasmic hyaline inclusions of familial amyotrophic lateral sclerosis with posterior column involvement. J Neuropathol Exp Neurol. 55(4), 481-490.
63) Singh, J., Sabareesan, A. T., Mathew, M. K., & Udgaonkar, J. B. (2012). Development of the structural core and of conformational heterogeneity during the conversion of oligomers of the mouse prion protein to worm-like amyloid fibrils. J Mol Biol. 423(2), 217-231.
64) Soon, C. P. W., Donnelly, P. S., Turner, B. J., Hung, L. W., Crouch, P. J., Sherratt, N. A., et al. (2011). Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J Biol Chem. 286(51), 44035-44044.
65) Tanaka, N., Kimura, S., Kamatari, Y. O., Nakata, K., Kobatake, Y., Inden, M., et al. (2021). In vitro evidence of propagation of superoxide dismutase-1 protein aggregation in canine degenerative myelopathy. Vet J. 274, 105710.
66) Tartaglia, G. G., & Vendruscolo, M. (2008). The Zyggregator method for predicting protein aggregation propensities. Chem Soc Rev. 37(7), 1395-1401.
67) Thornton, J. M. (1981). Disulphide bridges in globular proteins. J Mol Biol. 151(2), 261- 287.
68) Toichi, K., Yamanaka, K., & Furukawa, Y. (2013). Disulfide scrambling describes the oligomer formation of superoxide dismutase (SOD1) proteins in the familial form of amyotrophic lateral sclerosis. J Biol Chem. 288(7), 4970-4980.
69) Turner, B. J., & Talbot, K. (2008). Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol. 85(1), 94-134.
70) Wang, R., Yang, B., & Zhang, D. (2011). Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model. Glia. 59(6), 946-958.
71) Watanabe, H., Ono, M., Kimura, H., Matsumura, K., Yoshimura, M., Okamoto, Y., et al. (2012). Synthesis and biological evaluation of novel oxindole derivatives for imaging neurofibrillary tangles in Alzheimer's disease. Bioorg Med Chem Lett. 22(17), 5700-5703.
72) Werner, T. E. R., Bernson, D., Esbjorner, E. K., Rocha, S., & Wittung-Stafshede, P. (2020). Amyloid formation of fish beta-parvalbumin involves primary nucleation triggered by disulfide-bridged protein dimers. Proc Natl Acad Sci U S A. 117(45), 27997-28004.
73) Williams, J. R., Trias, E., Beilby, P. R., Lopez, N. I., Labut, E. M., Bradford, C. S., et al. (2016). Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co-expressing the Copper-Chaperone-for-SOD. Neurobiol Dis. 89, 1-9.
74) Wininger, F. A., Zeng, R., Johnson, G. S., Katz, M. L., Johnson, G. C., Bush, W. W., et al. (2011). Degenerative myelopathy in a Bernese Mountain Dog with a novel SOD1 missense mutation. J Vet Intern Med. 25(5), 1166-1170.
75) Wong, H. E., Irwin, J. A., & Kwon, I. (2013). Halogenation generates effective modulators of amyloid-Beta aggregation and neurotoxicity. PLoS One. 8(2), e57288.
76) Xue, C., Lin, T. Y., Chang, D., & Guo, Z. (2017). Thioflavin T as an amyloid dye: fibril quantification, optimal concentration and effect on aggregation. R Soc Open Sci. 4(1), 160696.
77) Yokota, S., Kobatake, Y., Noda, Y., Nakata, K., Yamato, O., Hara, H., et al. (2018). Activation of the unfolded protein response in canine degenerative myelopathy. Neurosci Lett. 687, 216-222.
78) Zeng, R., Coates, J. R., Johnson, G. C., Hansen, L., Awano, T., Kolicheski, A., et al. (2014). Breed distribution of SOD1 alleles previously associated with canine degenerative myelopathy. J Vet Intern Med. 28(2), 515-521.
79) Zhang, Q., & Kelly, J. W. (2003). Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions. Biochemistry. 42(29), 8756-8761.
論文の公開元へ
